WE'RE DEDICATED TO FINDING ATREATMENT FOR SMA
In collaboration with Astellas, Cytokinetics is developing CK-2127107 (CK-107), a fast skeletal troponin activator (FSTA) as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with neuromuscular or non-neuromuscular dysfunction, muscular weakness, and/or muscle fatigue.
Like tirasemtiv, CK-107, an investigational drug candidate, is intended to slow the rate of calcium release from the regulatory troponin complex of fast skeletal muscle fibers. CK-107 is a next-generation skeletal muscle compound that may improve muscle function and physical performance in people with SMA and COPD.
CK-107 has been the subject of five completed Phase 1 clinical trials in healthy volunteers, which evaluated safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics. It is currently the subject of two Phase 2 clinical trials, one assessing its effect on multiple measures of muscle function in patients with Type II, Type III, or Type IV SMA, and one evaluating its effect on physical function and exercise tolerance in patients with COPD.
Cytokinetics and Astellas recently amended their collaboration to enable the development of CK-107 for the potential treatment of ALS.